Parkinson's Disease: LRRK2

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement. This feed focuses on leucine-rich repeat kinase 2 (LRRK2) which is the most prominent genetic contributor to PD.

January 21, 2022

Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.

Movement Disorders : Official Journal of the Movement Disorder Society
Alicia GarridoRubén Fernández-Santiago
January 20, 2022
Open Access

Regulators of proteostasis are translationally repressed in fibroblasts from sporadic and LRRK2-G2019S Parkinson's patients

BioRxiv : the Preprint Server for Biology
D. FlinkmanEleanor Coffey
January 20, 2022

Bioengineered models of Parkinson's disease using patient-derived dopaminergic neurons exhibit distinct biological profiles in a 3D microenvironment.

Cellular and Molecular Life Sciences : CMLS
Nicholas J FioreDavid L Kaplan
January 16, 2022

Clinical and imaging evidence of brain-first and body-first Parkinson's disease.

Neurobiology of Disease
Jacob HorsagerMichael Sommerauer
January 15, 2022

LRRK2 R1441C mutation causing Parkinson's Disease in an Egyptian family.

Neurologia i neurochirurgia polska
Shan Ali, Zbigniew K Wszolek
January 12, 2022
Open Access

LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights.

Patrick D SkeltonLoukia Parisiadou
January 12, 2022
Open Access

Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain.

Molecular Neurodegeneration
Enquan XuAndrew B West
January 11, 2022
Open Access

Cognitive Impairment in Genetic Parkinson's Disease.

Parkinson's Disease
A Planas-Ballvé, D Vilas
January 8, 2022

LRRK2 and idiopathic Parkinson's disease.

Trends in Neurosciences
Emily M RochaJ Timothy Greenamyre
January 8, 2022

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.

European Journal of Medicinal Chemistry
Robert K LeśniakThomas J Montine
December 31, 2021

Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors.

Journal of Medicinal Chemistry
Mitchell H KeylorPeter H Fuller
December 31, 2021
Open Access

Influence of N6-Methyladenosine Modification Gene HNRNPC on Cell Phenotype in Parkinson's Disease.

Parkinson's Disease
Wei QuanJiajun Chen
December 28, 2021
Open Access

Mitochondrial Function and Parkinson's Disease: From the Perspective of the Electron Transport Chain.

Frontiers in Molecular Neuroscience
Jeng-Lin LiChih-Chiang Chan
December 21, 2021

LRRK2 correlates with macrophage infiltration in pan-cancer.

Jing YanBaoliang Zhu
December 17, 2021

Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-α Pathway.

Movement Disorders : Official Journal of the Movement Disorder Society
Chin-Hsien LinMing-Shiang Wu
December 14, 2021

LRRK2 signaling in neurodegeneration: two decades of progress.

Essays in Biochemistry
Lucia Iannotta, Elisa Greggio
December 7, 2021

In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.

Neurobiology of Disease
Salvatore NovelloMichele Morari

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2022 Meta ULC. All rights reserved